Becton Dickinson And Company Stock News

IHI: A Standout Performer With Equally Strong Future Growth Prospects

Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry Global Market Report 2022, By Type, By Technology, By End User, By Application" report has been added to ResearchAndMarkets.com''s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global flow cytometry market. The report gives a guide to the flow cytometry market which will be shaping and changing our lives over the next ten years and beyond, including the market''s response to the challenge of the global pandemic Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market.

It's holding up without breaking a sweat.

Upcoming Ex-Dividend Dates: March 1-9, 2021

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

Riding The Stock Waves: Update On The Medical Devices Sector

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Chemotherapy Devices Market finds that increasing prevalence of cancer is expediting market growth. Primarily driven by increasing cardiovascular surgeries and diagnostics, the total Global Chemotherapy Devices Market is estimated to reach USD 23.12 Billion by 2028 . The Market stood at a revenue of USD 11.54 Billion in the year 2021, and is expected to exhibit a Compound Annual Growth Rate (CAGR) of 7.5%. Furthermore, the increase in technological advancements is also anticipated to augment the growth of the Global Chemotherapy Devices Market, states Vantage Market Research, in a report, titled " Chemotherapy Devices Market by Product (Catheter, Cannula, Pump, Others), by Application (Hospital, Clinics, Home Care), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/chemotherapy-devices-market-1310/request-sample (The Free Sample Of This Report Is Readily Available On Request).

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

Becton, Dickinson And Co. (BDX) shares closed today at 1.2% below its 52 week high of $280.62, giving the company a market cap of $78B. The stock is currently up 10.2% year-to-date, up 10.6% over the past 12 months, and up 66.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.0%. Trading Activity Trading volume this week was 3.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -267.3% The company's stock price performance over the past 12 months beats the peer average by 3.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 77.5% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Diamond Hill Capital (Trades, Portfolio) recently disclosed its 13F portfolio updates for the fourth quarter of 2021, which ended on Dec. 31.

Becton, Dickinson And Co. (BDX) shares closed today at 1.1% below its 52 week high of $272.36, giving the company a market cap of $76B. The stock is currently up 6.9% year-to-date, up 7.0% over the past 12 months, and up 60.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Trading volume this week was 1.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -184.9% The company's stock price performance over the past 12 months lags the peer average by -15.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 76.9% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Becton, Dickinson and Company (BDX) stock has been a bright spot this year, gaining 6.9% so far.

Becton, Dickinson And Co. (BDX) shares closed today at 1.3% below its 52 week high of $272.36, giving the company a market cap of $76B. The stock is currently up 6.9% year-to-date, up 6.9% over the past 12 months, and up 59.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Trading volume this week was 86.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 3.1% higher than its 5-day moving average, 3.4% higher than its 20-day moving average, and 7.9% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -184.9% The company's stock price performance over the past 12 months lags the peer average by -23.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.8% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.